26 / 53
ALK-TKI Resistance Mechanisms
Crizotinib-resistant cases
Second-generation(CER, ALC, BRG)
ALK TKI–resistant cases
Gainor JF, et al. Cancer Discov., 2016
Major resistance
mechanism
Non-
mutational
Not enough
exposure of Criz
Bypass signaling
50-70%
Major resistance
mechanism
Secondary
ALK mutations
50-70%